We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (383)
- Scheduling (national classification system) (164)
- Safety monitoring and information (26)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Medicinal cannabis hub (6)
- Clinical trials (5)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
758 result(s) found, displaying 276 to 300
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - June 2021 ACMS meeting
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - June 2021 Joint ACMS-ACCS meeting
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - June 2021 ACCS meeting
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - June 2021 Joint ACMS-ACCS meeting
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - June 2021 ACMS meeting
-
Scheduling decisions (final)Final decisions on proposed amendments to the Poisons Standard relating to MDMA and psilocybin.
-
Corporate reportsPublication of the independent expert review of MDMA and psilocybin.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 1 November 2021.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closed 1 November 2021.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closed: 11 November 2021.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closed: 11 November 2021
-
Meeting statementsAdvisory Committee on Vaccines. Meeting statement available.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement available.
-
Scheduling submissionsPublic submissions on interim decisions for scheduling matters referred to ACMS, ACCS and Joint meetings held in March 2021
-
Scheduling submissionsPublic submissions on interim decisions for scheduling matters referred to ACMS, ACCS and Joint meetings held in March 2021
-
Corporate reportsThe Freedom of Information disclosure log gives access to information we've released in response to an FOI request.
-
Corporate reportsThe TGA thanks respondents who provided a submission in response to the public consultation paper Proposed refinements to the regulation of personalised medical devices.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Corporate reportsThe TGA 2020-21 Annual Performance Statistics Report has now been published.
-
Scheduling submissionsPublic submissions made in response to the public consultation on proposed amendments to the Poisons Standard - March 2021 ACMS/ACCS meetings
-
Corporate reportsIn the past 12-18 months, the TGA has implemented a number of changes in an effort to increase and improve post-market monitoring and surveillance activities
-
Corporate reportsThe guidelines set out the criteria which must be met for any additional manufacturing sites to be included as secondary sites on new or existing manufacturing licences.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closed: 11 November 2021
-
Meeting statementsAdvisory Committee on Medical Devices meeting statement available